Results 41 to 50 of about 377,889 (137)

Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. [PDF]

PLoS ONE, 2010
BACKGROUND: Better delivery systems are needed for routinely used vaccines, to improve vaccine uptake. Many vaccines contain alum or alum based adjuvants. Here we investigate a novel dry-coated densely-packed micro-projection array skin patch (Nanopatch™)
Holly J Corbett, Germain J P Fernando, Xianfeng Chen, Ian H Frazer, Mark A F Kendall   +4 more
doaj   +1 more source

Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom

Journal of Health Economics and Outcomes Research, 2022
# Background The United Kingdom (UK) switched from using the 4-valent human papillomavirus (HPV) vaccine (Gardasil®) to the 9-valent vaccine (Gardasil 9®) in 2021. # Objective To estimate and compare the health and economic outcomes of 2 HPV vaccination
Kwame Owusu-Edusei, Cody Palmer, Olga Ovcinnikova, Giampiero Favato, Vincent Daniels   +4 more
doaj   +2 more sources

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

HPV Vaccine Gardasil®-9 : What You Need to Know [PDF]

, 2015
This paper describes Gardasil®-9, its risks, and what to do if there is a serious ...
South Carolina Department of Health and Environmental Control
core  

Influenza and Human Papillomavirus Vaccine Utilisation in Vulnerable Urban Youth in Edmonton, Alberta, Canada

The International Journal of Health Planning and Management, Volume 41, Issue 4, Page 572-579, July 2026.
ABSTRACT Introduction This project explores influenza and human papillomavirus (HPV) vaccine utilisation among a multi‐ethnic group of youth (aged 11–23 years) in Edmonton, Alberta, Canada. Method Using a cross‐sectional design and purposive sampling, influenza vaccine utilisation over 3 years was assessed via questionnaire.
Sarah Deck, Se Lim Jang, Rachel Harris, Fariba Kolahdooz, Moutasem Zakkar, Sangita Sharma   +5 more
wiley   +1 more source

University of Montana Students and the Gardasil Vaccine [PDF]

, 2017
Gardasil® is a vaccine for human papilloma virus (HPV), a sexually transmitted virus that can cause genital warts, cervical cancer, and other diseases. Males and females ages 9-26 are recommended to receive the Gardasil® vaccination.
Glidewell, Markie C
core   +1 more source

Ongoing challenges and future directions of human papillomavirus vaccination

Безопасность и риск фармакотерапии, 2020
Cervical cancer caused by human papillomavirus (HPV) types 16 and 18 is one of the most common cancer types in women. Other high-risk HPV types may cause vaginal cancer, vulval cancer, penile cancer, anal cancer, head and neck cancer. Low-risk HPV types,
O. S. Alyautdina, V. Yu. Prilutskaya
doaj   +1 more source

Human Papillomavirus: Update in Bridging Basic Science to Clinical and Public Health Innovations

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Human papillomavirus (HPV), a non‐enveloped, double‐strand DNA viral pathogen, is intricately linked with the onset of various cancers, including cervical cancer and head and neck cancers. The present paper delves into HPV's ancient recognition and significant milestones such as the discovery of its role in oncogenesis and the development of ...
Fatemeh Beygnejad, Narges Eslami, Kaveh Gharaei Nejad, Atefeh Zamani Kermanshahi, Hossein Bannazadeh Baghi   +4 more
wiley   +1 more source

Primary Cancer Prevention Through Vaccination: Advances, Challenges, and Global Perspectives

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Oncogenic viral and bacterial infections constitute a significant portion of the global cancer burden, accounting for up to 15% of cases, particularly in low‐ and middle‐income countries. Prophylactic vaccination thus appears to be the most effective tool for preventing these preventable cancers, especially those linked to human papillomavirus
Christian Tague, Johan Domga, Ayesha Junaid, Okhesomi Rejoice Eshemokhai, Josias Kamgang Silatchom, Criss Koba Mjumbe   +5 more
wiley   +1 more source

Nonavalent HPV vaccine to prevent recurrent anal or vulvar high‐grade squamous intraepithelial lesions (VIVA trial): A randomized, double‐blind, placebo‐controlled trial

International Journal of Cancer, Volume 158, Issue 11, Page 2983-2994, 1 June 2026.
What's new? Anal and vulvar high‐grade squamous intraepithelial lesions (HSILs) frequently recur following treatment. Additional genital and anal procedures, however, can be distressing for patients and are potentially disfiguring. This trial assessed whether the 9‐valent human papillomavirus (9vHPV) vaccine reduces HSIL recurrence risk or HPV ...
Helen C. Stankiewicz Karita, Amalia S. Magaret, David R. Doody, Jeffrey T. Schouten, Constance Mao, Warner K. Huh, Verena S. Grieco, Matthew A. Seymour, Dana Varon, Kelly H. Shrader, Long Fu Xi, Denise A. Galloway, Anna Wald, Margaret M. Madeleine   +13 more
wiley   +1 more source